( )
we use cookies
DeclineAccept
Founded in 2018 in Boston, 1910 Genetics began with two AI platforms, ELVIS for small molecule drugs and ROSALYND for protein therapeutics, and one aim: "to make undruggable targets a thing of the past".
In 2026 it relaunched as 1910 and put the platform to work across pharma, as "an infrastructure for AI-enabled drug discovery". The stated ambition goes further: to make every pharma company an AI company.
The second engagement started where the first ended, with a different company: a new offering, a new positioning and everything rebuilt from the start, colour, symbol and system, while the core message and the founding vision stayed. The technology would no longer be explained in an image and a short clip; it would be walked through, component by component, each backed by the scientific logic and the proof behind it. The look and feel: an enterprise-grade company, confident in the rooms it now enters.
A new identity, the website, the founder video and the full explainer of the ITO™ platform in its three parts, AI-driven Precision Target ID, AI-driven Molecular Design & Optimization and Federated Learning, launched in February 2026, five years after the studio's first brand and website for the company.
That earlier engagement launched in late 2020; the following March the company debuted publicly with $26M, per GlobeNewswire. From there the company went on to $40M in all, across seed, Series A and Series A-2, per its investor page, and came to 2026 with a platform proven and a position to take.
01:32
Play
